Approval · Notice of Compliance 9040 · 2007
CUBICIN: Notice of Compliance 9040
Issued September 24, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9040
- Date
- September 24, 2007
- Company
- Cubist Pharmaceuticals Llc6005 Luzern, Luzern, Switzerland
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: staphylococcus aureus bloodstream infections (bacteremia) including those with right-sided staphylococcus aureus infective endocarditis (native valve) caused by methicillin-susceptible and methicillin-resistant strains
- Therapeutic class
- Antibacterial agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CUBICIN | Not yet assigned | — |
Medicinal ingredients
- DAPTOMYCIN 500 MG per VIAL